Jason Gerberry
Stock Analyst at B of A Securities
(3.98)
# 729
Out of 4,479 analysts
94
Total ratings
59.46%
Success rate
6.89%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $21 → $20 | $11.87 | +68.49% | 3 | Jun 11, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Buy | $18 → $21 | $16.55 | +26.89% | 8 | May 30, 2024 | |
| PROK ProKidney | Maintains: Neutral | $3 → $4 | $2.24 | +78.57% | 2 | May 29, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $82 → $91 | $68.54 | +32.77% | 1 | Apr 17, 2024 | |
| GLPG Galapagos NV | Downgrades: Underperform | $41 → $31 | $25.34 | +22.34% | 5 | Apr 1, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $12 → $11 | $0.28 | +3,828.57% | 3 | Mar 25, 2024 | |
| CPRX Catalyst Pharmaceuticals | Initiates: Buy | $23 | $15.80 | +45.57% | 1 | Mar 7, 2024 | |
| ALKS Alkermes | Maintains: Neutral | $27 → $29 | $24.19 | +19.88% | 5 | Jan 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $29 → $37 | $25.22 | +46.71% | 2 | Jan 2, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $67 → $80 | $76.06 | +5.18% | 2 | Jan 2, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $52 → $56 | $36.56 | +53.17% | 2 | Jan 2, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $52 → $62 | $45.14 | +37.35% | 3 | Jan 2, 2024 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Underperform | $30 | $30.00 | - | 2 | Jan 2, 2024 | |
| BLUE bluebird bio | Maintains: Buy | $12 → $5 | $0.92 | +441.65% | 6 | Dec 21, 2023 | |
| IMVT Immunovant | Maintains: Buy | $49 → $51 | $26.52 | +92.31% | 3 | Dec 21, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Neutral | $63 | $37.58 | +67.64% | 1 | Nov 17, 2023 | |
| VTRS Viatris | Downgrades: Underperform | $9 | $10.43 | -13.71% | 2 | Oct 23, 2023 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $204 → $217 | $105.09 | +106.49% | 3 | Aug 10, 2023 | |
| FGEN FibroGen | Downgrades: Underperform | $4 → $2 | $0.74 | +169.18% | 6 | Aug 8, 2023 | |
| AXSM Axsome Therapeutics | Upgrades: Neutral | $59 → $81 | $78.93 | +2.62% | 2 | Aug 8, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $450 → $500 | $906.71 | -44.86% | 5 | May 24, 2023 | |
| CARA Cara Therapeutics | Maintains: Underperform | $6 → $4 | $0.28 | +1,339.37% | 2 | May 16, 2023 | |
| ACLX Arcellx | Maintains: Buy | $39 → $50 | $53.25 | -6.10% | 3 | May 10, 2023 | |
| ALLO Allogene Therapeutics | Downgrades: Underperform | $9 | $2.16 | +316.67% | 1 | Dec 12, 2022 | |
| OGN Organon & Co. | Downgrades: Underperform | $37 → $25 | $20.12 | +24.25% | 3 | Oct 14, 2022 | |
| BYSI BeyondSpring | Downgrades: Underperform | n/a | $2.36 | - | 2 | Dec 2, 2021 | |
| BHC Bausch Health Companies | Downgrades: Underperform | n/a | $7.11 | - | 2 | Mar 24, 2021 | |
| CHRS Coherus BioSciences | Initiates: Neutral | n/a | $1.39 | - | 1 | Jul 16, 2020 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Neutral | n/a | $7.47 | - | 1 | Jul 15, 2020 | |
| PFE Pfizer | Maintains: Buy | n/a | $27.83 | - | 2 | Apr 1, 2019 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | n/a | $40.45 | - | 4 | Feb 19, 2019 | |
| ABBV AbbVie | Maintains: Buy | n/a | $165.96 | - | 3 | Oct 4, 2018 | |
| MRK Merck & Co. | Maintains: Buy | n/a | $127.72 | - | 3 | Jul 30, 2018 |
Oculis Holding AG
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $11.87
Upside: +68.49%
Teva Pharmaceutical
May 30, 2024
Maintains: Buy
Price Target: $18 → $21
Current: $16.55
Upside: +26.89%
ProKidney
May 29, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $2.24
Upside: +78.57%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $82 → $91
Current: $68.54
Upside: +32.77%
Galapagos NV
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $25.34
Upside: +22.34%
Lyra Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.28
Upside: +3,828.57%
Catalyst Pharmaceuticals
Mar 7, 2024
Initiates: Buy
Price Target: $23
Current: $15.80
Upside: +45.57%
Alkermes
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $24.19
Upside: +19.88%
Arrowhead Pharmaceuticals
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $25.22
Upside: +46.71%
Vaxcyte
Jan 2, 2024
Maintains: Buy
Price Target: $67 → $80
Current: $76.06
Upside: +5.18%
Xenon Pharmaceuticals
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $36.56
Upside: +53.17%
Ionis Pharmaceuticals
Jan 2, 2024
Upgrades: Buy
Price Target: $52 → $62
Current: $45.14
Upside: +37.35%
Harmony Biosciences Holdings
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $30.00
Upside: -
bluebird bio
Dec 21, 2023
Maintains: Buy
Price Target: $12 → $5
Current: $0.92
Upside: +441.65%
Immunovant
Dec 21, 2023
Maintains: Buy
Price Target: $49 → $51
Current: $26.52
Upside: +92.31%
Amphastar Pharmaceuticals
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $37.58
Upside: +67.64%
Viatris
Oct 23, 2023
Downgrades: Underperform
Price Target: $9
Current: $10.43
Upside: -13.71%
Jazz Pharmaceuticals
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $105.09
Upside: +106.49%
FibroGen
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.74
Upside: +169.18%
Axsome Therapeutics
Aug 8, 2023
Upgrades: Neutral
Price Target: $59 → $81
Current: $78.93
Upside: +2.62%
Eli Lilly
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $906.71
Upside: -44.86%
Cara Therapeutics
May 16, 2023
Maintains: Underperform
Price Target: $6 → $4
Current: $0.28
Upside: +1,339.37%
Arcellx
May 10, 2023
Maintains: Buy
Price Target: $39 → $50
Current: $53.25
Upside: -6.10%
Allogene Therapeutics
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.16
Upside: +316.67%
Organon & Co.
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $20.12
Upside: +24.25%
BeyondSpring
Dec 2, 2021
Downgrades: Underperform
Price Target: n/a
Current: $2.36
Upside: -
Bausch Health Companies
Mar 24, 2021
Downgrades: Underperform
Price Target: n/a
Current: $7.11
Upside: -
Coherus BioSciences
Jul 16, 2020
Initiates: Neutral
Price Target: n/a
Current: $1.39
Upside: -
Verrica Pharmaceuticals
Jul 15, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.47
Upside: -
Pfizer
Apr 1, 2019
Maintains: Buy
Price Target: n/a
Current: $27.83
Upside: -
Bristol-Myers Squibb Company
Feb 19, 2019
Maintains: Neutral
Price Target: n/a
Current: $40.45
Upside: -
AbbVie
Oct 4, 2018
Maintains: Buy
Price Target: n/a
Current: $165.96
Upside: -
Merck & Co.
Jul 30, 2018
Maintains: Buy
Price Target: n/a
Current: $127.72
Upside: -